A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream (PAC-14028) may be effective for treating atopic dermatitis, one of the most common inflammatory skin diseases.

The trial involved a cream that blocks the transient receptor potential vanilloid subfamily, member 1, an involved in the perception of pain. This channel also contributes to inflammation and itchy skin in patients with .

In the 8-week, randomized, double-blind, multicentre, study that enrolled 194 adults with mild to moderate atopic dermatitis, the cream improved clinical symptoms and signs with a favourable safety profile.

According to the authors, a phase III clinical trial is underway to test if the topical medicine is safe and effective in teens and adults.

More information: British Journal of Dermatology (2019). DOI: 10.1111/bjd.17455

Journal information: British Journal of Dermatology

Provided by Wiley